22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure

Kidney International

Volumn 55, Issue 3, 1999, Pages 821-832

  Monier Faugere, Marie Claude ^b   Geng, Zhaopo ^b   Friedler, Robert M ^b   Qi, Quanle ^b   Kubodera, Noboru ^b   Slatopolsky, Eduardo ^b   Malluche, Hartmut H ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b NONE

Author keywords

Adynamic bone disease; Calcitriol; Hypercalcemia; Hyperphosphatemia; Parathyroid hormone

Indexed keywords

22 OXACALCITRIOL; CALCITRIOL; CALCIUM; PARATHYROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE BIOPSY; BONE DISEASE; BONE METABOLISM; BONE TURNOVER; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DOG; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM;

EID: 0002859068     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.055003821.x     Document Type: Article

References (67)

1. 3 in the management of renal osteodystrophy. Kidney Int 19:409-418, 1980
2. Voigts AL, Felsenfeld AJ, Llach F: The effects of calciferol and its metabolites on patients with chronic renal failure. Arch Int Med 143:1205-1211, 1983
3. 3 administration on bone in patients with renal failure. Kidney Int 38(Suppl):S48-S53, 1990
4. Coburn JW: Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney Int 38(Suppl 29):S54-S61, 1990
5. Malluche HH, Faugere MC: Renal bone disease 1990: An unmet challenge for the nephrologist. Kidney Int 38:193-211, 1990
6. Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez, J: Calcium carbonate is an effective phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315:157-161, 1986
7. Fournier A, Moriniere P, Sebert JL, Okhissi H, Atik A, Leflon P, Renaud H, Gueris J, Gregoire I, Idrissi A, Garabedian M: Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia. Kidney Int 29(Suppl 18):S114-S119, 1986
8. 3 administration in moderate renal failure: A prospective double-blind trial. Kidney Int 35:661-669, 1989
9. Malluche HH, Faugere M-C: Risk of adynamic bone disease in dialyzed patients. Kidney Int 42:62-67, 1992
10. Quarles LD, Davidai GA, Schwab SJ, Bartholomay DW, Lobaugh B: Oral calcitriol and calcium: Efficient therapy for uremic hyperparathyroidism. Kidney Int 34:840-844, 1988
11. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74:2136-2143, 1984
12. 3 pulse therapy. Nephron 51:130-131, 1989
13. Quarles L, Yohay D, Carroll BA, Spritzer C, Minda S, Bartholomay D, Lobaugh B: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 45:1710-1721, 1994
14. Faugere M, Friedler R, Malluche H: Efficacy and limitations of pulse I.V. and pulse oral therapy on bone disease in patients on chronic dialysis, (abstract) J Am Soc Nephrol 5:695, 1993
15. Quarles LD, Indridason OS: Calcitriol administration in end-stage renal disease: Intravenous or oral. Pediatr Nephrol 10:331-336, 1996
16. Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB: Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:1160-1166, 1994
17. 3 analogues. Chem Pharm Bull (Tokyo) 34:4410-4413, 1986
18. Brown AJ, Ritter CR, Finch JL, Morrissey J, Martin KJ, Murayama E, Nishii Y, Slatopolsky E: The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 84:728-732, 1989
19. Naveh-Many T, Silver J: Effects of calcitriol, 22-oxacalcitriol, and calcipotriol on serum calcium and parathyroid hormone gene expression. Endocrinology 133:2724-2728, 1993
20. Fukagawa M, Kaname S, Igarashi T, Ogata E, Kurokawa K: Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int 39:874-881, 1991
21. 3, on bone mineral metabolism in normal male rats. Calcif Tissue Int 50:521-523, 1992
22. Brown AJ, Finch JL, Lopez-Hilker S, Dusso A, Ritter C, Pernalete N, Slatopolsky E: New active analogues of vitamin D with low calcemic activity. Kidney Int 38:S22-S27, 1990
23. Kubrusly M, Gagné E, Ureña P, Hanrotel C, Chabanis S, Lacour B, Drüeke TB: Effect of 22-oxa-calcitriol on calcium metabolism in rats with severe secondary hyperparathyroidism. Kidney Int 44:551-556, 1993
24. 3, is effective in suppressing secondary hyperparathyroidism in uremic rats. (abstract) J Am Soc Nephrol 4:719, 1993
25. Takahashi F, Furuichi T, Yorozu K, Abe Y, Kubodera N, Slatopolsky E: Effect of intravenous 22-oxacalcitriol on secondary hyperparathyroidism in dogs with chronic renal failure. (abstract) J Am Soc Nephrol 5:890, 1994
26. 3 and 22-oxacalcitriol prevent decrease in vitamin D receptor content in the parathyroid glands of uremic rats. Kidney Int 50:34-39, 1996
27. 3 with an oxygen atom in the side chain. FEBS Lett 226:58-62, 1987
28. Abe J, Takita Y, Nakano T, Miyaura C, Suda T, Nishii Y: A novel synthetic analogue of vitamin D3, 22-OXA-1a, 25-dihydroxyvitamin D3, is a potent modulator of in vivo immuno-regulating activity without inducing hypercalcemia in mice. Endocrinology 124:2645-2647, 1989
29. 3. J Bone Miner Res 7:835-839, 1992
30. Brown AJ, Finch J, Grieff M, Ritter C, Kubodera N, Nishii Y, Slatopolsky E: The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine. Endocrinology 133:1158-1164, 1993
31. Brown A, Dusso A, Slatopolsky E: Selective vitamin D analogs and their therapeutic applications. Semin Nephrol 14:156-174, 1994
32. Friedlaender MM, Yagil Y, Wald H, Popovtzer MM: 22-Oxacalcitriol does not interfere with parathyroid hormone-induced phosphaturia or cyclic-AMP excretion. Bone 17:301-306, 1995
33. 3 on bone metabolism in young-X-linked hypophosphatemic male mice. Am J Physiol (Endocrinol Metab) 33:E141-E147, 1996
34. 3 on the proliferation of pancreatic cancer cell lines. Gastroenterology 110:1605-1613, 1996
35. 3 for 1,25-dihydroxyvitamin D receptor and its effects on the synthesis of osteocalcin in human osteosarcoma cells. Biochem Biophys Res Commun 16:629-635, 1990
36. Pernalete N, Mori T, Nishii Y, Slatopolsky E, Brown AJ: The activity of 22-oxacalcitriol in osteoblast-like (ROS 17/2.8) cells. Endocrinology 129:778-784, 1991
37. 3 analogs potently induce the human osteocalcin gene promoter stably transfected in rat osteosarcoma cells (ROSCO-2). J Bone Miner Res 6:893-899, 1991
38. 2+ entry-stimulating pathways. Am J Physiol 265:F705-F711, 1993
39. 3 in vivo nuclear receptor binding in developing bone during endochondral and intramembranous ossification. Histochemistry 102:183-194, 1994
40. Kanatani M, Sugimoto T, Kaji H, Kano J, Chihara K: Effects of 22-oxacalcitriol on bone metabolism in vitro: Comparison with calcitriol. Effects of 22-oxacalcitriol on osteoclast-like cell formation and bone-resorbing activity. Eur J Endocrinol 1133:618-625, 1995
41. 3 (ED-71), on bone metabolism in organ culture. Bone 14:47-51, 1993
42. Matsuzaki M, Shimamoto Y, Watanabe M, Kukita A, Yoshida S, Tadano J: Intracellular multiplication of legionella pneumophila in HL-60 cells functionally differentiated in response to 22-oxacalcitriol. J Leukoc Biol 57:574-580, 1995
43. Platt R, Roscoe MH, Smith FW: Experimental renal failure. Clin Sci (Colch) 2:217-231, 1952
44. Friedler RM, Massry SG, Kurokawa K, Coburn JW: Renal action of cholera toxin. I. Effects on urinary excretion of electrolytes and cyclic AMP. Kidney Int 7:77-85, 1975
45. Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nazawa-Ung K, Kim LY, Kentmann HT, Wang CA, Potts JT, Segre GV: Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33:1364-1367, 1988
46. Torrance AG, Nachreiner R: Human-parathormone assay for use in dogs: Validation, sample handling studies, and parathyroid function testing. Am J Vet Res 50:1123-1127, 1989
47. Fanti P, Colombo G, Yao C, Brown SA, Vernon MW, Malluche, HH: Development and characterization of polyclonal antiserum-based radioimmunoassay for dog osteocalcin. J Bone Miner Res 8:745-752, 1993
48. Hollis BW: Assay of circulating 1,25-dihydroxyvitamin D involving a novel single cartridge extraction and purification procedure. Clin Chem 32:2060-2063, 1986
49. Malluche HH, Faugere MC: Atlas of Mineralized Bone Histology. New York, Karger, 1986
50. Goldner J: A modification of the Masson trichrome technique for routine laboratory purposes. Am J Pathol 14:237-243, 1938
51. Manaka RC, Malluche HH: A program package for quantitative analysis of histologic structure and remodeling dynamics of bone. Comput Programs Biomed 13:191-202, 1981
52. Malluche HH, Meyer W, Sherman D, Massry SG: Quantitative bone histology in 84 normal American subjects: Micromorphometric analysis and evaluation of variance of iliac bone. Calcif Tissue Int 34:449-455, 1982
53. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche HH, Meunier PJ, Ott SM, Recker RR: Bone histomorphometry: Standardization of nomenclature, symbols and units. J Bone Miner Res 6:595-610, 1987
54. Exploring Data, in SPSS for Windows Base System User's Guide (release 6.0). Chicago, SPSS, Inc., 1993
55. Kurokawa K, Akizawa T, Suzuki M, Akiba T, Ogata E, Slatopolsky E: Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: Results of a preliminary study. Nephrol Dial Transplant 11:121-124, 1996
56. Dusso AS, Negrea L, Finch J, Kamimura S, Lopez-Hilker S, Mori T, Nishii Y, Brown A, Slatopolsky E: The effect of 22-oxacalcitriol on serum calcitriol. Endocrinology 130:3129-3134, 1992
57. Grieff M, Dusso A, Mori T, Nishii Y, Slatopolsky E, Brown AJ: 22-oxacalcitriol suppresses 25-hydroxycholecalciferol-1α-hydroxylase in rat kidney. Biochem Biophys Res Commun 185:191-196, 1992
58. Akeno N, Saikatsu S, Kimura S, Horiuchi N: Induction of vitamin D 24-hydroxylase messenger RNA and activity by 22-oxacalcitriol in mouse kidney and duodenum. Biochem Pharmacol 48:2081-2090, 1994
59. Dusso AS, Negrea L, Gunawardhana S, Lopez-Hilker S, Finch J, Mori T, Nishii Y, Slatopolsky E, Brown AJ: On the mechanisms for the selective action of vitamin D analogs. Endocrinology 128:1687-1692, 1991
60. 3. II. Effects on histopathology of bone: Evidence for healing of osteomalacia. Miner Electrolyte Metab 2:48-55, 1979
61. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274-279, 1989
62. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH: Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 26:622-631, 1995
63. Hruska K, Teitelbaum S: Renal osteodystrophy. N Engl J Med 333:166-174, 1995
64. Tanaka H, Hruska KA, Malone JD, Nishii Y, Teitelbaum SL: Dissociation of the macrophage-maturational effects of vitamin D from respiratory burst priming. J Biol Chem 266:10888-10892, 1991
65. 3. Proc Natl Acad Sci USA 78:4990-4994, 1981
66. 3 and 22-oxa-calcitriol on skeletal growth in X-linked hypophosphatemic mice. (abstract) Ann Orthop Res Soc 40:340, 1994
67. Kurz P, Monier-Faugere M-C, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH: Calcium kinetics in patients with renal osteodystrophy: Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46:855-861, 1994